What it's for (Indications)
- Bisoprolol + Hydrochlorothiazide is indicated for the management of essential hypertension.
- This fixed-dose combination therapy is generally recommended for patients whose blood pressure is not adequately controlled with monotherapy of either bisoprolol or hydrochlorothiazide alone, or for initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.
- The synergistic action of the beta-blocker (bisoprolol) and the thiazide diuretic (hydrochlorothiazide) provides effective blood pressure reduction by targeting different physiological mechanisms involved in hypertension, thereby offering a comprehensive approach to blood pressure control and improving adherence by simplifying dosing regimens.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of bisoprolol/hydrochlorothiazide must be individualized based on the patient's therapeutic response and tolerability, and typically administered once daily. For initial therapy or for patients not adequately controlled on monotherapy, a common starting dose is 2.5 mg of bisoprolol and 6.25 mg of hydrochlorothiazide. The dose may be gradually increased at intervals of 1 to 2 weeks, up to a maximum recommended daily dose of 10 mg bisoprolol/25 mg hydrochlorothiazide. It is crucial to monitor blood pressure regularly, and assess for potential adverse effects, particularly bradycardia, hypotension, and electrolyte disturbances, during all dose adjustments. Dosage adjustments may be necessary in patients with renal or hepatic impairment, and elderly patients may require lower starting doses due to potentially altered pharmacokinetics. |
Safety & Warnings
Common Side Effects
- Common side effects associated with bisoprolol/hydrochlorothiazide include, but are not limited to, fatigue, dizziness, headache, bradycardia (slow heart rate), hypotension, peripheral edema, nausea, diarrhea, and sexual dysfunction.
- Due to the hydrochlorothiazide component, electrolyte imbalances such as hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia can occur, as can hyperglycemia, hyperuricemia, and increased cholesterol and triglyceride levels.
- Less common but potentially serious adverse effects may include bronchospasm (especially in susceptible individuals), exacerbation of heart failure, masked symptoms of hypoglycemia in diabetic patients, acute kidney injury, and rarely, blood dyscrasias, photosensitivity reactions, or acute angle-closure glaucoma.
- Patients should report any persistent, worsening, or severe symptoms to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: Bisoprolol, like other beta-adrenergic blocking agents, should generally not be withdrawn abruptly, especially in patients with ischemic heart disease. Abrupt cessation has been associated with exacerbation of angina pectoris, myocardial infarction, and ventricular arrhythmias. Patients should be warned against interruption or discontinuation of therapy without their physician's advice. When discontinuing chronically administered bisoprolol, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1 to 2 weeks, if possible, under careful medical supervision. If angina worsens or acute coronary insufficiency develops, bisoprolol administration should be reinstituted promptly, at least temporarily. Close patient monitoring during this period is essential. This critical safety concern applies to any medication containing a beta-blocker component, including bisoprolol/hydrochlorothiazide combinations, and necessitates careful patient education regarding the risks of unsupervised discontinuation.
- Special caution is warranted when administering bisoprolol/hydrochlorothiazide to patients with a history of heart failure, as beta-blockers can depress myocardial contractility and precipitate or worsen cardiac failure; close monitoring for signs of decompensation is essential.
- In diabetic patients, bisoprolol can mask symptoms of hypoglycemia and may worsen glucose control; careful monitoring of blood glucose is advised.
- Use with caution in patients with asthma or other bronchospastic conditions, as bisoprolol, even at therapeutic doses, can cause bronchoconstriction.
- Patients undergoing surgery should inform their anesthesiologist about bisoprolol therapy due to potential interactions with anesthetic agents.
- Regular monitoring of serum electrolytes (e.
- g.
- , potassium, sodium, magnesium, calcium), renal function, and uric acid levels is crucial due to the hydrochlorothiazide component.
- Hydrochlorothiazide may exacerbate or activate systemic lupus erythematosus, and can cause idiosyncratic reactions leading to transient myopia and acute angle-closure glaucoma, necessitating immediate discontinuation.
How it Works (Mechanism of Action)
Bisoprolol + Hydrochlorothiazide is a combination antihypertensive therapy comprising a beta-1 selective adrenergic blocking agent (bisoprolol) and a thiazide diuretic (hydrochlorothiazide). Bisoprolol primarily antagonizes beta-1 adrenergic receptors in the heart, leading to a dose-dependent decrease in heart rate, myocardial contractility, and cardiac output, which collectively contribute to blood pressure reduction. It also inhibits the release of renin from the kidneys. Hydrochlorothiazide, a benzothiadiazine derivative, exerts its diuretic and antihypertensive effects by inhibiting sodium chloride reabsorption in the cortical diluting segment of the distal convoluted tubule of the nephron. This action leads to increased urinary excretion of sodium, chloride, and water, along with increased potassium and hydrogen ion excretion. The net effect is a reduction in plasma volume, peripheral vascular resistance, and consequently, blood pressure. The combination provides additive antihypertensive effects through distinct and complementary mechanisms, often allowing for lower doses of each component and improved tolerability.
Commercial Brands (Alternatives)
No other brands found for this formula.